William J. Peters, the Chief Financial Officer, Executive Vice President, and Treasurer of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), recently sold shares of the company. According to a recent SEC filing, Peters sold 7,426 shares of Amphastar common stock on November 6, 2024, at a price of $52.05 per share, totaling approximately $386,523.
This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which Peters adopted on March 14, 2024. Following this sale, Peters holds 94,103 shares directly.
In addition to the sale, Peters also exercised stock options to acquire 7,426 shares at a price of $13.03 per share, with a total transaction value of $96,760. These stock options were fully vested and immediately exercisable. After the option exercise, Peters' direct ownership amounts to 23,674 shares.
In other recent news, Amphastar Pharmaceuticals Inc. conducted its third-quarter earnings call, where the company's financial results and future expectations were discussed. The call was led by senior executives, including CFO Bill Peters, and touched on forward-looking statements and non-GAAP measures. These statements, the company emphasized, are based on currently available information and could be influenced by various factors impacting future performance.
The company's management provided their outlook for future periods, which included forward-looking statements. However, they also reminded that these statements are subject to numerous factors that may impact future performance, as indicated in SEC filings and on the company's website. The discussion of non-GAAP measures suggests a focus on providing investors with a clear understanding of the company's financials beyond standard accounting practices.
Following the formal presentation, a question-and-answer session was announced, allowing participants to engage with the company's executives. These are among the recent developments at Amphastar Pharmaceuticals Inc.
InvestingPro Insights
While William J. Peters' recent stock sale might raise eyebrows, a closer look at Amphastar Pharmaceuticals' financial metrics and market performance provides valuable context. According to InvestingPro data, Amphastar boasts a market capitalization of $2.34 billion and a P/E ratio of 15.04, suggesting a relatively modest valuation for a company in the pharmaceutical sector.
One InvestingPro Tip highlights that Amphastar's management has been aggressively buying back shares, which often signals confidence in the company's future prospects and can potentially boost shareholder value. This buyback activity aligns with the company's strong financial position, as another InvestingPro Tip notes that Amphastar's liquid assets exceed its short-term obligations, indicating solid financial health.
The company's revenue growth is noteworthy, with a 20.33% increase over the last twelve months as of Q3 2024, reaching $723.55 million. This growth is complemented by a robust gross profit margin of 52.92% and an operating income margin of 29.29%, underscoring Amphastar's operational efficiency.
Despite the recent insider sale, Amphastar's stock has shown resilience, with a 9.19% price total return over the past six months. The company's fair value, based on analyst targets, stands at $57.50, suggesting potential upside from its previous closing price of $46.09.
For investors seeking a more comprehensive analysis, InvestingPro offers additional insights with 10 tips available for Amphastar Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.